Doris Schueler Pa Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 426 Harvard Ave., S. Plainfield, NJ 07080 Phone: 908-756-8989 Fax: 908-756-0150 |
News Archive
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
A study led by researchers at the Hospital del Mar Medical Research Institute and the Institute of Medical Physics and Biophysics at the Faculty of Medicine in Charité Hospital, Berlin, published in the journal Nature Communications, demonstrates that the cholesterol present in cell membranes can interfere with the function of an important brain membrane protein, through a previously unknown mode of interaction.
Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it is the first CRO on the West Coast to acquire the Xcelodose system, enhancing the company's preclinical and early phase clinical GMP supply capabilities.
Birmingham scientists have made a genetic breakthrough in tracing the cause of a rare kidney and liver disorder. ARC syndrome means babies are born with impairment to kidney and liver function, bleeding problems and weak muscles. This usually leads to early death. The gene which causes this condition has been identified.
A new Boston University School of Public Health (BUSPH) study finds a substantial increase in the number and strength of state laws to reduce impaired driving over the last 20 years, while laws to reduce excessive drinking remained unchanged.
› Verified 7 days ago